FY2025 EPS Estimates for Tourmaline Bio Lifted by Analyst

Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) - Chardan Capital increased their FY2025 earnings per share estimates for Tourmaline Bio in a report released on Monday, May 5th. Chardan Capital analyst D. Gataulin now forecasts that the company will post earnings of ($3.93) per share for the year, up from their prior forecast of ($4.10). Chardan Capital currently has a "Buy" rating and a $70.00 target price on the stock. The consensus estimate for Tourmaline Bio's current full-year earnings is ($3.02) per share. Chardan Capital also issued estimates for Tourmaline Bio's FY2026 earnings at ($4.72) EPS.

A number of other brokerages have also recently commented on TRML. Lifesci Capital initiated coverage on Tourmaline Bio in a research note on Monday, February 24th. They set an "outperform" rating and a $58.00 price objective for the company. HC Wainwright reaffirmed a "buy" rating and set a $50.00 price objective on shares of Tourmaline Bio in a research report on Monday, May 5th. Finally, Wedbush raised their price target on Tourmaline Bio from $42.00 to $43.00 and gave the company an "outperform" rating in a research note on Friday, March 14th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $49.33.

Tourmaline Bio Trading Down 3.8%

Shares of TRML traded down $0.60 during trading hours on Thursday, hitting $15.18. 93,791 shares of the stock traded hands, compared to its average volume of 270,046. Tourmaline Bio has a 1-year low of $11.56 and a 1-year high of $29.79. The firm has a market capitalization of $389.90 million, a PE ratio of -5.38 and a beta of 2.11. The business has a fifty day moving average of $15.54 and a 200-day moving average of $18.57.

Tourmaline Bio (NASDAQ:TRML - Get Free Report) last announced its quarterly earnings results on Friday, May 2nd. The company reported ($0.89) earnings per share for the quarter, beating analysts' consensus estimates of ($0.91) by $0.02.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Brooklyn Investment Group acquired a new position in Tourmaline Bio during the 4th quarter worth approximately $32,000. Tower Research Capital LLC TRC grew its holdings in shares of Tourmaline Bio by 297.6% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,646 shares of the company's stock valued at $33,000 after acquiring an additional 1,232 shares in the last quarter. KLP Kapitalforvaltning AS bought a new position in Tourmaline Bio during the fourth quarter valued at $47,000. Virtus ETF Advisers LLC bought a new position in Tourmaline Bio during the fourth quarter valued at $64,000. Finally, GAMMA Investing LLC lifted its position in shares of Tourmaline Bio by 4,481.7% during the first quarter. GAMMA Investing LLC now owns 7,514 shares of the company's stock worth $114,000 after acquiring an additional 7,350 shares in the last quarter. 91.89% of the stock is owned by institutional investors and hedge funds.

About Tourmaline Bio

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.